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Maspin is a unique member of the serpin family, which functions as a class II tumor suppressor gene. Despite its known
activity against tumor invasion and motility, little is known about maspin’s functions in normal mammary gland
development. In this paper, we show that maspin does not act as a tPA inhibitor in the mammary gland. However, targeted
expression of maspin by the whey acidic protein gene promoter inhibits the development of lobular–alveolar structures
during pregnancy and disrupts mammary gland differentiation. Apoptosis was increased in alveolar cells from transgenic
mammary glands at midpregnancy. However, the rate of proliferation was increased in early lactating glands to compensate
for the retarded development during pregnancy. These findings demonstrate that maspin plays an important role in
mammary development and that its effect is stage dependent. © 1999 Academic PressKey Words: maspin; serpin; lobular–alveolar structure; mammary development; whey acidic protein.
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Serine protease inhibitors (serpins) comprise a large fam-
ily of molecules that play a variety of physiological roles in
vivo. Serpins can be divided into two categories: inhibitory
nd noninhibitory serpins. Noninhibitory serpins, typified
y ovalbumin and PEDF, do not exhibit protease inhibitor
ctivity, but rather function as a storage protein and inducer
f cell differentiation, respectively (Hunt and Dayhoff,
980; Tombran-Tink et al., 1992). Inhibitory serpins ablate
serine proteases through their functional domain-reactive
site loop (RSL) (Potempa et al., 1994). Interestingly, some
nhibitory serpins have evolved other regulatory functions.
or example, plasminogen activator inhibitor 1 (PAI-1) not
nly specifically inhibits tPA and uPA, but also regulates
ell adhesion, which is independent of its protease inhibitor
unction, by blocking integrin avb3 binding to vitronectin
(Stefansson and Lawrence, 1996; Deng et al., 1996).
Maspin is a unique member of the serpin family that
shares extensive homology with PAI-1 and other serpins
1 To whom correspondence should be addressed at the Depart-
ment of Cell Biology, Baylor College of Medicine, One Baylor Plaza,
Houston, Texas 77030. Fax: (713) 798-8012. E-mail: mzhang@
bcm.tmc.edu.
278Zou et al., 1994). Initially identified as a class II tumor
uppressor gene, maspin has been shown to inhibit invasion
nd motility of mammary carcinoma cells in culture (Zou
t al., 1994; Sheng et al., 1996; Zhang et al., 1997a). Tumor
transfectants expressing maspin exhibit decreased growth
and metastasis in nude mice (Zou et al., 1994). Maspin gene
expression is not detected in most breast tumors and loss of
its expression is correlated with tumor invasiveness (Zhang
et al., 1997b). In human breast tissue, maspin is produced
predominantly by myoepithelial cells and it has been sug-
gested that these maspin-expressing cells form a defensive
barrier for the progression from ductal carcinoma in situ to
more invasive carcinomas (Sternlicht et al., 1997).
Structurally, maspin has a unique RSL different from that
of other inhibitory serpins (Fitzpatrick et al., 1996; Hopkins
and Whisstock, 1994). It has been shown that the short RSL
in maspin presents a structural difficulty that would not
allow maspin to undergo the stressed-to-relaxed transition,
a feature characteristic of noninhibitory serpins (Pemberton
et al., 1995). However, a recent report by Sheng et al.
emonstrated that maspin could specifically function as a
rotease inhibitor by blocking tissue plasminogen activator
n vitro (Sheng et al., 1998). This observation led to theconclusion that maspin’s anti-protease activity was respon-
sible for its ability to inhibit tumor cell invasion and
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279Maspin in Mammary Gland Developmentmotility (Sheng et al., 1994, 1998). However, the biological
relevance of a maspin/tPA interaction has not been con-
firmed in vivo.
The murine mammary gland undergoes cycles of growth,
morphogenesis, and involution throughout development.
Interactions between epithelial cells and the extracellular
matrix (ECM) play an essential role in mammary gland
development (Talhouck et al., 1991; Sympson et al., 1994).
Disruption of cell adhesion disrupts normal mammary
morphogenesis and differentiation (Faraldo et al., 1998).
Indeed, destruction of the ECM by proteases, which disrupt
cell–cell and cell–basement membrane contacts, has a
similar defect in mammary development (Alexander et al.,
1996; Sympson et al., 1994; Talhouk et al., 1992; Witty et
al., 1995). To delineate maspin’s function in vivo, we have
generated transgenic mice that overexpress maspin in the
mammary gland under the control of the WAP (whey acidic
protein; Hennighausen et al., 1982) gene promoter. Since
maspin is expressed in mammary epithelial cells, as is the
WAP gene, and WAP expression begins at midpregnancy
and remains on throughout lactation (Pittius et al., 1988),
this study assessed the effect of maspin transgene expres-
sion on normal mammary gland development during this
time frame. Our data demonstrate that overexpression of
maspin by the WAP promoter inhibits alveolar develop-
ment and differentiation.
MATERIAL AND METHODS
Mice
For phenotypic comparisons (histology, RNA, protein), all mice
in this study were age matched with wild-type littermates as
controls. Virgin mice were between 7 and 8 weeks. Unless other-
wise indicated, mice between 7 and 8 weeks of age were used for
mating. Timed pregnancy was determined by plug appearance and
confirmed by delivery. Involution was forced by removing the pups
from the mother at lactation day 10 except for the RT-PCR assay,
when pups were taken from mother at lactation day 21. For each
time point, samples from at least two transgenic and wild-type
mice were examined.
Zymogram Gel
The activity of plasminogen activators (tPA and uPA) in mam-
mary gland was detected in casein gels supplemented with plas-
minogen as described by Talhouk et al. (1991). Fresh samples from
mammary tissues were frozen in liquid nitrogen. Tissue was then
pulverized into a fine powder and suspended 1:5 (wt/vol) in
extraction buffer (1% Triton X-100, 500 mM Tris–HCl buffer, pH
7.6, 200 mM NaCl, 10 mM CaCl2). The suspension was frozen on
dry ice and thawed four times and microfuged (12,000g for 30 min).
he supernatant was used for zymogram gel. Each sample loaded
ontained 15 mg protein. For casein gels, 12% polyacrylmide with
1 mg/ml purified casein (Sigma, Inc., St. Louis, MO) was prepared
with plasminogen (6 mg/ml; American Diagnostica, Inc., CT).
urified single-chain tPA was purchased from American Diagnos-
ica and 0.2 ng (0.1 IU) tPA was used per lane (commercial tPA
ample contains a small amount of uPA activity). Recombinant
b
(
Copyright © 1999 by Academic Press. All rightaspin was prepared as described before (Zhang et al., 1997a) and
oncentrated by centrifugation in Centracon (Micron, Inc., MA).
he tPA present in mammary gland (15 mg extract) was quantitated
by comparing its activity to that of a purified tPA control. The level
of tPA in virgin or pregnant mammary gland (15 mg extract) was
stimated at about 0.1 ng. To characterize the effect of maspin on
lasminogen activators, mammary protein extracts or purified tPA
0.2 ng) were either incubated with concentrated maspin (2 mg in
5-ml reaction solution of 2.6 mM) or mock treated for 30 min at
37°C before mixing with 43 SDS sample buffer. The molar ratio of
maspin to tPA was calculated to exceed 20,000 to 1 in reactions
containing mammary extracts. After electrophoresis, the zymo-
gram gel was incubated in a sealed plastic bag with concentrated
maspin at 10 mM or as a control with PMSF at the recommended
concentration of 5 mM for a period of 24 h in 50 mM Tris–HCl, 10
mM CaCl2, pH 7.6. The gel was then stained with Coomassie Blue
R250 for 45 min and photographed.
Whole-Mount Preparations
For whole-mount comparison, two samples from each time
point were examined. Mammary gland whole mounts were per-
formed by spreading the fourth inguinal gland on a glass slide
followed by fixation in Carnoy’s solution for 60 min at room
temperature (Medina, 1973; Li et al., 1996). Following fixation, the
land was dehydrated by 70% EtOH, followed by staining with
armine alum overnight (0.2% carmine, 0.5% aluminum sulfate).
he tissue then was dehydrated and mounted on glass slides using
outine methods.
Histology and Immunostaining
Mammary glands were removed under anesthesia from normal
and transgenic females at different stages of development. Unless
mentioned in the text, the samples were taken from left or right
inguinal No. 4 mammary gland for histology. Mammary tissues
were fixed in 10% neutral formalin buffer and embedded in paraffin
and sectioned at 5 mm. PCNA staining was performed as recom-
mended by the manufacturer (Zymed, Inc., San Francisco, CA).
TUNEL assay was carried out as described by Li et al. (1995)
utilizing a TDT nick end-labeling kit by Boehringer Mannheim
(Boehringer Mannheim, Inc., Mannheim, Germany).
Generation of Transgenic Mice
The WAP–maspin vector (Fig. 3A) was generated by PCR ampli-
fication of the mouse maspin coding region (Zhang et al., 1997a)
with primers flanked by KpnI and Sal I sites (59-CGGTACCGGAT-
CCATGGATGCCCTGAGACTGGCA-39 and 59-TCCCCCGGG-
TCGACTACAGACAAGTTCCCTGAGA-39). After ligating the
mouse maspin cDNA between WAP exon 1 and 3, the maspin
cDNA portion was sequenced to ensure the absence of mutations.
The vector was digested with NotI and HindIII and the lineralized
WAP–maspin construct was injected into C57BL/6 3 BALB/c F1
fertilized eggs. The injected embryos were transferred into oviducts
of recipient pseudo-pregnant female C57BL/6 mice, and the off-
spring were analyzed by Southern blot. Six transgenic founders
were generated and crossed with C57BL/6 mice to generate F1 lines.
wo of the best expressing lines of maspin transgenics were
stablished for further analysis, and positive litters were screened
y PCR analysis using the following primers. Endogenous maspin
199 bp): 59 primer, GATGGTGGTGAGTCCATC; 39 primer, TC-
s of reproduction in any form reserved.
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280 Zhang et al.CCCCGGGTCGACTACAGACAAGTTCCCTGAGA. Transgene
(218 bp): 59 primer, GATGGTGGTGAGTCCATC; 39 primer,
GCTCTAGAGGTGTACATGTCATGACACAGTCGAC.
For RT-PCR identification of transgene and endogenous maspin
mRNAs (RT-PCR is not used to quantitate the difference of
expression level in this case), the 39 primers of transgene and
endogenous maspin above were used for reverse transcription. Both
transgene and endogenous maspin products were PCR amplified
with the above sets of primers. PCR was carried out for 35 cycles in
two sets of identical reaction conditions (95°C for 1 min, 52°C for
1 min, 72°C for 1 min 30 s, 34 cycles).
Northern Blot Analysis
RNA was isolated by guanidine as previously described
(Swisshelm et al., 1994). Total RNA was fractionated on 1%
agarose–1.7 M formaldehyde gels, transferred to a Zetaprobe (Bio-
Rad Laboratories, Richmond, CA) membrane in 203 SSC, and
aked for 1 h at 80°C. Blots were probed with a 1.5-kb EcoRI/XhoI
ragment from the mouse maspin cDNA plasmid. Ribosomal
rotein gene 36B4 was used as an internal loading and transfer
ontrol (Laborda, 1991).
Western Blot Analysis
The mouse mammary tissues were frozen in liquid N2 and lysed
n electrophoresis sample buffer (Zou et al., 1994; Zhang et al.,
997a), and the extracts were subjected to electrophoresis on a 10%
DS–polyacrylamide gel and transferred to Immobilon membrane.
or b-casein and WAP protein analysis, 20 mg of whole extract for
ach sample was loaded for transfer. The blot was exposed first to
nti-WAP antibody and reexposed to anti-b-casein antibody. For
anti-WAP antibody, a 1:1000 dilution was used and followed by
exposure to a 1:2500 dilution of peroxidase-conjugated goat anti-
rabbit IgG polyclonal antibody (Amersham, Arlington Heights, IL)
as described (Li et al., 1996). Anti-rat b-casein monoclonal antibody
kindly provided by Dr. Jeff Rosen’s laboratory) was originally a gift
rom Dr. Mina Bissell. A dilution of 1:2500 was used for this
ntibody followed by an exposure to a 1:2500 dilution of sheep
FIG. 1. Northern blot analysis of maspin gene in normal mouse
mammary glands during development. Each lane contains 10 mg of
total RNAs. Samples are from virgin (lanes 1, 2), day 10 pregnant
(lanes 3, 4), day 19 pregnant (lanes 5, 6), day 3 lactation (lanes 7, 8),
day 3 involution (lanes 9, 10), and day 10 involution (lanes 11, 12).
The blot was hybridized with a cDNA probe for mouse maspin.
The ribosomal protein gene 36B4 was used as a loading and transfer
control.
Copyright © 1999 by Academic Press. All rightnti-mouse IgG (HRP conjugated) (Amersham). The blot was finally
robed with an anti-b-actin monoclonal antibody (Sigma) at a
1:2500 dilution followed by an exposure to a 1:10,000 sheep
anti-mouse IgG (HRP conjugated) (Amersham).
RESULTS
Maspin Does Not Act as a tPA Inhibitor
in Mammary Gland
To determine the temporal expression of maspin during
mammary gland development, Northern blot assays were
performed (Fig. 1). Maspin mRNA was expressed at rela-
tively low levels in virgin and early pregnant mammary
glands; however, maspin gene expression increased during
late pregnancy and lactation. Following involution, maspin
mRNA levels decreased to those observed in the prepreg-
nant stage (lanes 11 and 12).
To delineate whether maspin regulated protease activity
in the mammary gland, SDS–PAGE containing casein and
plasminogen was carried out using mammary samples
obtained at different stages of development. The activities
of 48- (uPA) and 68-kDa (tPA) were observed in casein/
plasminogen gels as previously reported (Talhouk et al.,
991; Lund et al., 1996) (Fig. 2). The tPA activity was high
n virgin and pregnancy and low in lactation but began to
levate 3 days after forced involution. It was estimated that
he mammary gland (15 mg extract from virgin or pregnant
tage) contained less than 0.1 ng tPA (see Material and
ethods). As shown in Fig. 2, pretreatment of mammary
xtracts or pure tPA with maspin at 2.6 mM (molar ratio of
maspin to tPA exceeded 20,000 to 1) and continuous incu-
bation of the zymogram gel with maspin at 10 mM did not
inhibit the activity of tPA or uPA. However, recombinant
maspin used was functional against cell motility at submi-
cromolar concentration (data not shown). As a positive
control, treatment of the gel by PMSF, a nonspecific serine
FIG. 2. The effect of maspin on plasminogen activator activity
during mammary gland cycles assayed by SDS–substrate zymogra-
phy. Mammary samples from 8-week-old virgin (lanes 1, 6), day 15
pregnancy (lanes 2, 7), day 3 lactation (lanes 3, 8), day 3 involution
(lanes 4, 9), and pure tPA (lanes 5, 10) were assayed in casein/
plasminogen gel. Lanes 6–10 were duplicate samples of lanes 1–5
loaded on the same gel. Samples in lanes 6–10 were pretreated with
maspin at 2.6 mM and the gel was continuously incubated after
electrophoresis with maspin at 10 mM as described under Material
and Methods. All lanes were loaded with 15 mg of mammary
extracts or 0.2 ng of tPA control.protease inhibitor, effectively abolished tPA and uPA activ-
ity (data not shown).
s of reproduction in any form reserved.
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281Maspin in Mammary Gland DevelopmentWAP–Maspin Transgenic Mice
To further investigate the role of maspin in mammary
development, we utilized a transgenic mouse system to
examine the effect of overexpression of maspin under
control of the WAP promoter. The whey acidic protein has
been shown to be exclusively expressed in mammary epi-
thelial cells during midpregnancy and lactation.
Transgenic mice were generated by injecting embryos
with the construct as shown in Fig. 3A. Screening of
founders was performed by Southern blot analysis using
DNA isolated from mouse tissues (data not shown). Of the
FIG. 4. Whole-mount analysis of normal and transgenic mamma
analyses. The virgin mammary glands (V) were from age-matched vi
FIG. 3. WAP–maspin transgenic mice. (A) Schematic diagram of
digested by KpnI and Sal I to remove exons 1 and 2 and intron 1. T
and Sal I and ligated to the digested WAP plasmid to create the WA
of transgenic mice. RNAs (2 mg) from 8-week-old virgin (1, 6), day
9), and day 4 of involution (5, 10) samples were analyzed by RT-PC
number (1, 3, 5, 7, 9) gave rise to an endogenous maspin PCR pro
transgene transcript of 218 bp.were mated at 7 weeks of age for pregnancy. P10, 15, and 19 indicate da
power objective.
Copyright © 1999 by Academic Press. All rightix founder lines generated, two lines that displayed similar
henotypes were maintained and the results reported below
ere obtained from samples of the same line.
The expression of both endogenous maspin and the
ransgene in transgenic mouse mammary glands was exam-
ned qualitatively by reverse transcription-PCR (Fig. 3B).
NA was isolated from the mammary glands of transgenic
ice at different stages of development. As shown in Fig.
B, the PCR product of the transgene differed from that of
ndogenous maspin by 19 bp (218 bp vs 199 bp), allowing
hem to be distinguished by electrophoresis. As previously
nds during development. Inguinal No. 4 glands were taken for all
ransgenic and wild-type mice at 8 weeks of age. Age-matched mice
tructure of the WAP–maspin construct. WAP genomic DNA was
ouse maspin (mMaspin) cDNA (gray box) was digested with KpnI
aspin construct. (B) Expression of maspin in the mammary glands
f pregnancy (2, 7), day 19 of pregnancy (3, 8), day 3 of lactation (4,
th two sets of primers (see Material and Methods). Samples of odd
of 199 bp, while samples of even number (2, 4, 6, 8, 10) yielded ary gla
rgin tthe s
he m
P–m
15 o
R wiys 10, 15, and 19 of pregnancy. Photographs were taken with a 43
s of reproduction in any form reserved.
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283Maspin in Mammary Gland DevelopmentFIG. 5. Histological analysis of mammary tissues from the following mice: (A) wildtype at day 15 pregnancy, (B) transgenics at day 15
pregnancy, (C) wildtype at day 19 pregnancy, and (D) transgenics at day 19 pregnancy. (E and F) (Same magnification) High-power pictures
from (C) and (D), respectively. Note the reduced numbers of alveolar structures and the smaller lumen size in the transgenics (D, F).
Photographs were taken with a 103 objective for (A–D) and with a 403 objective for (E and F).
Copyright © 1999 by Academic Press. All rights of reproduction in any form reserved.
w
n
l
W
m
a
t
4
w
u
b
a
m
w
a
t
t
g
l
n
u
fi
c
t
a
I
d
b
I
t
l
s
c
l
f
t
w
a
o
t
w
d
p
t
w
n
h
p
284 Zhang et al.shown by Pittius et al. (1988), the WAP–maspin transgene
as expressed during late pregnancy and lactation, but was
ot detectable in virgin mice and glands undergoing invo-
ution (Fig. 3B).
To characterize the mammary gland phenotype of the
AP–maspin mice, whole-mount preparations of the mam-
ary glands from wild-type and transgenic mice were
nalyzed (Fig. 4). Ductal elongation and branching appeared
o be normal in wild-type and transgenic virgin mice (Fig.
). As shown in Fig. 4, no differences in alveolar structures
ere present between the transgenic and wild-type animals
p to day 10 of pregnancy; however, minor differences did
ecome noticeable at day 15 of pregnancy following the
ctivation of the WAP promoter-driven transgene. These
ammary glands exhibited decreased alveolar densities,
hich were further reduced compared to controls at day 19
nd resembled the morphology of the midpregnant wild-
ype controls.
This defect was also observed in histological samples
aken from mid- to late-pregnant transgenic mammary
lands (Fig. 5). A minor reduction in the numbers of
obular–alveolar structures was noted at day 15 of preg-
ancy in the transgenic line (Figs. 5A and 5B). The alveolar
nits in wild-type glands contained large lumens that were
lled with fat droplets at day 19 of pregnancy (Fig. 5C). In
ontrast, the mammary glands from transgenic mice con-
ained fewer lobular–alveoli structures, and the size of each
lveolar structure was greatly reduced (Figs. 5D, 5E, and 5F).
n many cases, the lumens of the alveoli were closed. This
efect was due to the expression of the transgene activated
y the WAP promoter from midpregnancy.
Increased Apoptosis and Proliferation in
Midpregnant and Early Lactating Mammary Gland
of Transgenic Mice
Since the underdevelopment of the mammary glands in
the WAP–maspin transgenic mice could have arisen from
either decreased proliferation or increased apoptosis or a
combination of the two, TUNEL and PCNA immunohisto-
chemistry assays were carried out utilizing pregnant and
early lactating mammary glands from wild-type and trans-
genic mice. As shown in Table 1, the apoptotic rate was
significantly increased in transgenic glands at midpreg-
nancy (2.29 6 0.26%) compared to controls (0.91 6 0.09%).
n contrast, little difference was observed in cell prolifera-
ion at day 15 of pregnancy (Table 2). However, during
actation, the apoptosis and proliferation profiles changed
ignificantly in the transgenic strain. Secretive alveolar
ells occupied the majority of the fat pad and there was a
ow rate of proliferation and apoptosis in samples taken
rom normal mammary glands. This observation contrasted
o the results obtained from the WAP–maspin mice, in
hich a large percentage of the fat pad was devoid of
lveolar cells and an increased rate of proliferation was
bserved (Table 2). Although apoptosis was still higher in
he transgenic glands than in normal control mice, there
Copyright © 1999 by Academic Press. All rightas a net increase in the number of alveolar cells between
ay 1 and day 10 lactation samples (data not shown). Both
roliferation and apoptosis index decreased quickly as lac-
ation proceeded and by lactation day 10, very few cells
ere PCNA-positive and apoptotic in both transgenic and
ormal mice.
Effect of Transgene Expression on Milk Gene
Expression
The defect in alveolar structures in the WAP–maspin
mice during late pregnancy severely hampered the ability of
the mother to successfully nurse her entire litter. Indeed,
most of the pups died due to insufficient milk production.
However, these pups could be rescued by fostering them to
a BALB/c nontransgenic lactating female. The number of
pups that a transgenic mother could nurse varied between
animals. A survey of five sibling mothers at their first
pregnancy yielded an average survival rate of 3.6 pups/litter.
Since milk protein genes can function as differentiation
markers for the mammary gland, we compared their expres-
sion patterns in transgenic and wild-type control mice.
Western blot analysis showed that WAP and b-casein were
ighly expressed in wild-type mammary glands at day 19 of
regnancy and during lactation (Fig. 6). However, WAP and
b-casein were not detectable in day-19 pregnant transgenic
mice (lanes 8 and 1). Both milk proteins were present in
lactating day 1 transgenic glands, but at a reduced levels,
which increased as lactation progressed (lanes 6 and 5). This
observed decrease was likely due to the effect of reduced
number of alveolar cells and closed lumens in the late-
pregnant transgenic mice.
DISCUSSION
We have demonstrated that maspin plays an important
role in mammary gland development. Targeted expression
of maspin, via the WAP promoter, inhibits alveolar devel-
opment by increasing apoptosis and disrupts the process of
differentiation. Since the transgene encodes the exact same
maspin protein as the endogenous gene in the same cells,
the phenotype is attributed directly to WAP–maspin over-
expression. The phenotype clearly depends upon the level
of transgene expressed, as not all of the transgenic lines
exhibit the same degree of alveolar disruption, which cor-
relates to WAP–maspin overexpression. Even though the
line tested displayed the most severe phenotype, due to the
patchy expression pattern of the WAP transgene (Sympson
et al., 1994), there are variations in alveolar structure, rate
of proliferation, and apoptosis (Tables 1 and 2). This also
resulted in decreased expression of endogenous maspin. In
some late-pregnant mammary glands that were severely
underdeveloped in the transgenic mice, overall maspin
levels were down because of the drastic decrease of epithe-
lial cells via increased apoptosis. Therefore, we did not use
total maspin protein as a marker in our characterization.
s of reproduction in any form reserved.
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285Maspin in Mammary Gland DevelopmentMaspin Does Not Act as a tPA Inhibitor
in Mammary Gland
Previous biochemical analysis demonstrated that maspin
could interact with single-chain tissue plasminogen activa-
tor and inhibit the conversion of plasminogen to plasmin
with a K i value of 0.13 mM (Sheng et al., 1998). Under
similar assay conditions, PAI-1 and PAI-2 also inhibited
tPA with a value either smaller than (PAI-1, 0.033 mM) or
imilar to (PAI-2, 0.55 mM) maspin (Sheng et al., 1998). It
as first suspected that maspin might act as a tPA inhibitor
uring mammary gland development. However, zymogra-
hy assay has excluded this possibility. In theory, inhibi-
ory serpin generally binds to its target protease in 1:1
toichiometry, inactivating the protease by forming a com-
lex stable to heat or SDS denaturation (Potempa et al.,
994; Pemberton et al., 1995). During the time of pretreat-
ent, the exogenous maspin was in such an excess
20,000:1) that we expected that it would at least decrease
he tPA activity should tPA be neutralized by maspin.
owever, this treatment and further incubation of the
ymogram gel for 24 h with maspin at 10 mM or about 803
i did not have any detectable inhibition of tPA activity.
e also compared the tPA activity of transgenic and wild-
ype mammary glands at various stages of mammary devel-
pment including midpregnancy and lactation by casein
ymography. No significant difference in tPA activity was
bserved (data not shown). Therefore, maspin’s mechanism
f action is unlikely to be mediated through tPA inhibition
TABLE 1
The Rate of Apoptosis in Wildtype and Transgenic Mice
WT Transgenic P value
15-day pregnant 0.91 6 0.09 (3) 2.29 6 0.26 (3) P , 0.01
19-day pregnant 0.54 6 0.05 (2) 0.91 6 0.54 (3) P , 0.04
Day 1 lactation 0.15 6 0.05 (2) 0.79 6 0.11 (3) P , 0.01
Note. Values are presented as percentages of apoptotic cells
(means 6 SD). Number of animals analyzed is indicated in paren-
theses. About 1000–1200 cells per sample were counted. Statistical
analysis was done by the Student t test.
TABLE 2
The Rate of Proliferation in Wildtype and Transgenic Mice
WT Transgenic P value
15-day pregnant 11.73 6 1.93 (4) 10.50 6 2.59 (4) P , 0.89
Day 1 lactation 2.73 6 1.72 (3) 9.49 6 1.86 (3) P , 0.01
Note. Values are presented as percentages of PCNA-positive
nuclei (means 6 SD). Number of animals analyzed is indicated in
parentheses. In all cases, 1000–1200 cells per sample were counted.
Statistical analysis was done by the Student t test.
Copyright © 1999 by Academic Press. All rightn the mammary gland. However, we cannot rule out the
ossibility that maspin may inhibit other unidentified
roteases in mammary gland. Alternatively, maspin may
ossess additional functions in mammary gland. We have
ecently found out that maspin acts as an angiogenesis
nhibitor, and this action is independent of the RSL domain
f maspin (Zhang et al., in review). It becomes more clear
hat the multifunctionality is a common feature for maspin
nd other serpins (Bajou et al., 1998; Deng et al., 1996).
Similar to studies that have been reported for PAI-1, we
elieve that maspin may primarily regulate cell adhesion
nd motility in mammary cells, possibly by regulating
ntegrin profiles. Indeed, expression of a dominant-negative
b1 integrin in the mammary gland, which disrupted the
function of b1 and its associated integrins, resulted in a
henotype similar to that observed in the WAP–maspin
ransgenic mice (Faraldo et al., 1998). Both maspin and
himeric b1 transgene expression caused underdevelop-
ent of the mammary gland in midpregnancy and early
actation, which was accompanied by an increase in apop-
osis. In early lactation, milk protein levels were also
educed. The similarity in phenotypes suggests that over-
xpression of maspin may act to perturb integrin regulation
r other associated cell adhesion molecules. This hypoth-
sis is partially supported by an in vitro study which
howed that exogenous maspin modified cell attachment to
bronection by regulating integrin profiles, including
own-regulation of b1 integrin (Seftor et al., 1998). How-
ever, there are some differences in the observed phenotype
between these two transgenic mice strains. For example,
FIG. 6. Western blot analysis of milk proteins in the mammary
glands of transgenic and nontransgenic C57BL/6 mice. Lanes 1–4
were from C57BL/6 mammary tissues and lanes 5–8 were from
transgenic mice. Age-matched samples used were from day 19 of
pregnancy (lanes 1, 8), day 1 of lactation (lanes 2, 7), day 3 of
lactation (lanes 3, 6), and day 10 of lactation (lanes 4, 5). Aliquots of
whole-cell extracts (20 mg) were loaded on each lane and separated
y 10% SDS–PAGE and transferred to PVDF membrane. The blot
as probed with antibodies against WAP, b-casein, and b-actin.
b-Actin was used as a loading and transfer control.the proliferation of alveolar cells in the b1-transgenic mice
decreases during pregnancy, while maspin transgenic mice
s of reproduction in any form reserved.
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286 Zhang et al.showed no change. Since alterations in integrin profiles,
especially the dimerization of subunits, are not well char-
acterized in the mammary gland, it is not known whether
other integrins or cell adhesion molecules are regulated by
maspin.
Disruption of the Process of Differentiation
at Midpregnancy
During pregnancy, alveolar cells proliferate and differen-
tiate. By parturition, the mammary gland terminally differ-
entiates and functions mainly to secrete milk for nursing
the progeny. Milk protein genes, such as WAP and b-casein,
are hallmarks of this process. In the WAP–maspin trans-
genic mice, we observed that WAP and b-casein gene
expression was diminished from late pregnancy to early
lactation, demonstrating that the differentiation process is
disrupted. This is reflected by the fact that the lumen of the
transgenic gland is reduced in size and closed during late
pregnancy compared to wild-type controls. This phenotype
correlates with other in vivo and in vitro studies, suggesting
hat the appropriate cell adhesion interactions between the
xtracellular matrix and epithelial cells are required for
ilk gene expressions (Alexander et al., 1996; Streuli et al.,
1995; Talhouk et al., 1992).
Increased Apoptosis in Pregnancy and
Proliferation in Lactation in Transgenic
Mammary Gland
We have shown that WAP–maspin transgene expression
significantly increases the rate of apoptosis in midpreg-
nancy, while the proliferation rate was largely unchanged.
The mechanism by which maspin regulates apoptosis is not
known. One possibility is that overexpression of maspin
perturbs the adhesion of alveolar cells to the ECM as does
the chimeric b1 transgene and thus inhibits the motility of
lveolar cells at a stage when invasion into the fat pad is
ritical. The proliferating alveolar cells are unable to mi-
rate out, leading to increased apoptosis and a resulting
mall lumen. This is consistent with the concept that
roper interactions of mammary epithelial cells with the
asement membrane are essential for cell survival, and
heir disruption will trigger signals leading to apoptosis
Frisch and Francis, 1994; Frisch and Ruoslahti, 1997).
During early lactation, the apoptotic rate in the WAP–
aspin mice is relatively higher than in wildtype, but is
ower than at midpregnancy. Proliferation is maintained at
high level, resulting in a net increase of alveolar cells.
nother finding is that the lumen, which is closed in late
regnancy, opens following parturition. The lumen is likely
pened in response to suckling (Li et al., 1997). However, it
s not clear why there is such an increase of proliferation in
arly lactation. In the normal gland, alveoli encompass the
ajority of the mammary fat pad by late pregnancy and arender the influence of estrogen and progesterone (Vonder-
aar et al., 1984). There is a transient surge of alveolar
Copyright © 1999 by Academic Press. All rightroliferation during early lactation, which allows these
lveoli to engorge the entire gland (Vonderhaar et al., 1988).
n the maspin transgenic mice, a compensatory prolifera-
ion of epithelial cells was observed to compensate for the
ncomplete alveolar development during pregnancy in order
o fulfill the physiological requirement to nurse the young.
In summary, we have demonstrated that maspin does not
ct to inhibit tPA, but may act primarily as a cell adhesion
nd motility regulator in mammary epithelial cells. To
onfirm this hypothesis, we are currently generating mice
ull for the maspin gene and assaying its role in normal
ammary gland development. By delineating maspin’s
echanism of action in vivo the role of maspin as a tumor
uppressor can be elucidated.
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